BioCentury
ARTICLE | Company News

Biotie, Roche deal

July 2, 2012 7:00 AM UTC

Biotie said Roche declined to exercise its option to regain rights to cognitive impairment product SYN120, citing "strategic portfolio reasons." The oral serotonin (5-HT6) receptor antagonist completed Phase I testing. According to Biotie, a number of companies have expressed interest in the compound and Biotie said it is confident it will find a partner. Details were not disclosed. ...